Drugs / BG505 MD39.3 gp151 mRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05217641 | Feb 2022 → Jul 2023 overdue | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG505 MD39.3 gp151 mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05217641 ↗ |
| Route | Intramuscular | “Administered by IM injection” NCT05217641 ↗ |